GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (OTCPK:ULIHF) » Definitions » Financial Strength

ULIHF (United Laboratories International Holdings) Financial Strength : 9 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is United Laboratories International Holdings Financial Strength?

United Laboratories International Holdings has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

United Laboratories International Holdings Ltd shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

United Laboratories International Holdings's Interest Coverage for the quarter that ended in Jun. 2024 was 77.17. United Laboratories International Holdings's debt to revenue ratio for the quarter that ended in Jun. 2024 was 0.17. As of today, United Laboratories International Holdings's Altman Z-Score is 3.50.


Competitive Comparison of United Laboratories International Holdings's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Financial Strength falls into.



United Laboratories International Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

United Laboratories International Holdings's Interest Expense for the months ended in Jun. 2024 was $-3 Mil. Its Operating Income for the months ended in Jun. 2024 was $268 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $199 Mil.

United Laboratories International Holdings's Interest Coverage for the quarter that ended in Jun. 2024 is

Interest Coverage=-1*Operating Income (Q: Jun. 2024 )/Interest Expense (Q: Jun. 2024 )
=-1*267.778/-3.47
=77.17

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. United Laboratories International Holdings Ltd has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

United Laboratories International Holdings's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(139.771 + 198.846) / 1978.25
=0.17

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

United Laboratories International Holdings has a Z-score of 3.50, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 3.5 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Laboratories International Holdings  (OTCPK:ULIHF) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

United Laboratories International Holdings has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.


United Laboratories International Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.

United Laboratories International Holdings Headlines

No Headlines